Fredag 18 April | 19:50:30 Europe / Stockholm
Svenska | English

Västra Hamnen Market Focus

Prenumeration

Xintela: Promising data for XSTEM in OA
2025-03-28 08:33:00
  • Q&A with CEO Evy Lundgren-Åkerlund
  • Strong support for advancing XSTEM in OA
  • We reiterate our fair value of SEK 1.43 per share

Xintela recently announced promising interim data from its phase I/IIa study with XSTEM in knee osteoarthritis (OA). Data from 24 patients in all three dose levels have been analysed, 18 months after treatment. No serious safety or tolerability issues were recorded in the study and the company also received promising early efficacy data. Västra Hamnen contacted CEO Evy Lundgren-Åkerlund for a comment.

Read the full report here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden